Shanghai Labway Clinical Laboratory Co Ltd (301060) — Strategic Asset Allocation Index
Shanghai Labway Clinical Laboratory Co Ltd (301060) has a Strategic Asset Allocation Index of 10.5% as of June 2023. Strategic assets (PP&E of CN¥223.80 Million plus long-term investments of CN¥-) total CN¥223.80 Million, measured against net assets of CN¥2.13 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Shanghai Labway Clinical Laboratory Co Ltd Strategic Asset Allocation Index (2019–2022)
This chart shows how Shanghai Labway Clinical Laboratory Co Ltd's Strategic Asset Allocation Index has evolved across 4 annual periods from 2019 to 2022. As of June 2023, the index stands at 10.5%, representing strategic assets of CN¥223.80 Million against net assets of CN¥2.13 Billion CNY. Explore 301060 cash flow metrics to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Shanghai Labway Clinical Laboratory Co Ltd (2019–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Shanghai Labway Clinical Laboratory Co Ltd from 2019 to 2022, covering 4 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see 301060 stock market capitalisation.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 9.7% | CN¥220.96 Million | CN¥220.96 Million | CN¥- | CN¥2.27 Billion | ▼ -5.0 pp |
| 2021 | 14.7% | CN¥241.11 Million | CN¥241.11 Million | CN¥- | CN¥1.64 Billion | ▲ +5.3 pp |
| 2020 | 9.4% | CN¥117.37 Million | CN¥117.37 Million | CN¥- | CN¥1.25 Billion | ▼ -1.6 pp |
| 2019 | 11.0% | CN¥133.08 Million | CN¥133.08 Million | CN¥- | CN¥1.21 Billion | — |